



PRESS RELEASE, MAY 13, 2013

MOBERG PHARMA AND PALADIN EXTENDS AGREEMENT FOR KERASAL NAIL™ TO MEXICO

Moberg Pharma AB (OMX: MOB) today announced that Paladin has been granted the exclusive rights to market and sell Kerasal Nail™ in Mexico. Kerasal Nail™ is an over-the-counter (OTC), topical product with a unique mechanism of action that generates visible improvements within 2-4 weeks of treatment. Further details or financial terms of the transaction were not disclosed.

"We are impressed by the resources Paladin are engaging in the forthcoming product launch in Canada and look forward to extend our collaboration. Mexico is a large and growing market and we expect Kerasal Nail™ to be equally well received as in the U.S. and many other markets, where the product has gained substantial market shares," said Peter Wolpert, President and CEO of Moberg Pharma AB.

About Kerasal Nail™ and nail disease

Kerasal Nail™ is a topical treatment used to treat nail disease. Launched in the Nordic region in late 2010, it quickly became the market leader. In the U.S. the product is sold over-the-counter under the name Kerasal Nail™, in other markets under the names Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Kerasal Nail™ has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments.

For further information, please contact:

Peter Wolpert, CEO

Telephone: +46 8 522 307 00

Mobile: +46 707 35 71 35

E-mail: peter.wolpert@mobergpharma.se

Magnus Persson, IR

Mobile: +46 733 55 26 01

E-mail: magnus.persson@mobergpharma.se

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 am (CET) on May 13, 2012.

About Moberg Pharma AB

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company's product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail® and Kaprolac®. Kerasal Nail® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.